Polaryx Therapeutics Inc
PLYX
13 hedge funds and large institutions have $5.83M invested in Polaryx Therapeutics Inc in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 3 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
0.16% less ownership
Funds ownership: 4.79% → 4.63% (-0.16%)
7% less funds holding
Funds holding: 14 → 13 (-1)
66% less capital invested
Capital invested by funds: $17.1M → $5.83M (-$11.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$322K |
| 2 |
Jane Street
New York
|
+$123K |
| 3 |
AF
Allworth Financial
Folsom,
California
|
+$30.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.79K |
| 5 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$2.02K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$102K |
| 2 |
Squarepoint
New York
|
-$93.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$47.9K |
| 4 |
Morgan Stanley
New York
|
-$41.9K |
| 5 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
-$2.02K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Capital Management
Malvern,
Pennsylvania
| $4.41M | -$2.02K | -516 | -0% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $455K | +$1.27K | +325 | +0.2% |
|
|
3
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
| $279K | +$2.02K | +516 | +0.5% |
|
|
HF
4
HRT Financial
New York
| $218K | +$322K | +82,094 | New |
|
5
State Street
Boston,
Massachusetts
| $155K | – | – | – |
|
6
BlackRock
New York
| $109K | – | – | – |
|
|
7
Jane Street
New York
| $83.6K | +$123K | +31,441 | New |
|
8
Northern Trust
Chicago,
Illinois
| $74.4K | – | – | – |
|
|
AF
9
Allworth Financial
Folsom,
California
| $20.6K | +$30.3K | +7,727 | New |
|
10
Vanguard Global Advisers
Malvern,
Pennsylvania
| $16.8K | – | – | – |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $7.99K | +$4.79K | +1,221 | +69% |
|
|
12
UBS Group
Zurich,
Switzerland
| $3.41K | -$47.9K | -12,196 | -90% |
|
|
FFO
13
Fortitude Family Office
Scottsdale,
Arizona
| $503 | +$742 | +189 | New |
|
|
14
Goldman Sachs
New York
| – | -$102K | -13,483 | Closed |
|
|
15
Squarepoint
New York
| – | -$93.8K | -12,406 | Closed |
|
|
16
Morgan Stanley
New York
| – | -$41.9K | -5,543 | Closed |
|
PLYX Hedge Fund Activity: Q2 2026 in Review
13 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Polaryx Therapeutics Inc (PLYX) for Q2 2026, worth a combined $5.83M — down 66% from $17.1M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PLYX positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 2 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $322K. The largest seller was Goldman Sachs, exiting entirely with an estimated $102K sold.
- 13 institutional investors held Polaryx Therapeutics Inc (PLYX) as of Q2 2026, down from 14 in Q1 2026.
- Funds reported $5.83M of Polaryx Therapeutics Inc stock for Q2 2026, down 66% quarter-over-quarter.
- 4 funds opened new Polaryx Therapeutics Inc positions in Q2 2026 and 3 closed out, a net change of +1 holder.
- The largest Polaryx Therapeutics Inc buyer in Q2 2026 was HRT Financial, an estimated $322K added.
- The largest Polaryx Therapeutics Inc seller in Q2 2026 was Goldman Sachs, an estimated $102K sold.
Based on aggregated 13F filings for Q2 2026.